FDA Approval for TRIKAFTA issued to VERTEX PHARMS INC

4/27/23 10:43:08 AM ET

$VRTX

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $VRTX alert in real time by email

New Drug Application (NDA): 217660
Company: VERTEX PHARMS INC

Products on NDA 217660

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
TRIKAFTA	ELEXACAFTOR;TEZACAFTOR;IVACAFTOR;IVACAFTOR	50MG;25MG;37.5MG;75MG	GRANULES;ORAL	Prescription	None	No	No

Approval Date(s) and History, Letters, Labels, Reviews for NDA 217660

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
04/26/2023	ORIG-1	Approval	Type 3 - New Dosage Form	PRIORITY; Orphan		Label is not available on this site.

Get the next $VRTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VRTX

Date	Price Target	Rating	Analyst
11/14/2024	$575.00	Buy	Citigroup
10/16/2024		Sector Perform	Scotiabank
10/10/2024		Mkt Perform	Raymond James
8/5/2024	$472.00 → $509.00	Overweight → Equal Weight	Barclays
6/27/2024	$545.00	Buy	Redburn Atlantic
4/11/2024	$438.00	In-line → Outperform	Evercore ISI
2/15/2024	$515.00	Outperform	Wolfe Research
2/6/2024	$436.00 → $438.00	Outperform → In-line	Evercore ISI

More analyst ratings

$VRTX
Leadership Updates

Live Leadership Updates

Vertex Appoints Nancy Thornberry to its Board of Directors
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director. Ms. Thornberry has more than 35 years of experience in the pharmaceutical and biotech industries, spanning drug discovery, development and commercialization. She founded and served as Chief Executive Officer of Kallyope until 2021 and remains on its Board of Directors and is Chair of Research & Development. Prior to joining Kallyope, Ms. Thornberry spent more than 30 years at Merck & Co., Inc., most recently as Senior Vice President and Global Franchise Head, Diabetes and Endocrinology, with responsibility for discovery and clinical
12/5/23 4:01:00 PM ET
$VRTX
Biotechnology: Pharmaceutical Preparations
Health Care
Vertex Appoints Michel Lagarde to its Board of Directors
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Michel Lagarde has been appointed to its Board of Directors as an independent director. Mr. Lagarde is a senior health care and business leader with global expertise, currently serving as Chief Operating Officer and Executive Vice President of Thermo Fisher Scientific Inc. Prior to Thermo Fisher, Mr. Lagarde served as President and Chief Operating Officer of Patheon, a contract manufacturer to the biopharma industry, and as a Managing Director at JLL Partners, a private equity firm investing in health care services. "We are delighted to have Michel join the Vertex Board. His deep experience across numerous segments of
10/5/23 8:00:00 AM ET
$VRTX
Biotechnology: Pharmaceutical Preparations
Health Care
Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that E. Morrey Atkinson, Ph.D., has been appointed Executive Vice President, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations, effective immediately. Dr. Atkinson has served as Senior Vice President of Global Commercial Manufacturing and Supply Chain since July 2020. This new role and function unifies responsibility for small molecule, cell and gene therapies across preclinical, clinical and commercial biopharmaceutical sciences, manufacturing operations and global supply chain. "Over the last three years, Morrey has played a vital role in building out our commercial manufa
8/29/23 9:00:00 AM ET
$VRTX
Biotechnology: Pharmaceutical Preparations
Health Care

$VRTX
Press Releases

Fastest customizable press release news feed in the world

Vertex Reports Third Quarter 2024 Financial Results
— Product revenue of $2.77 billion, a 12% increase compared to Q3 2023 — — Raising full-year product revenue guidance to $10.8 billion to $10.9 billion — — Preparing for two potential near-term launches: vanzacaftor triple in CF and suzetrigine (VX-548) for moderate-to-severe acute pain — — Pipeline progress continuing with three additional programs advancing to Phase 3: suzetrigine in DPN, povetacicept in IgAN and VX-880 in T1D — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the third quarter ended September 30, 2024, and raised its full-year product revenue guidance to $10.8 billion to $10.9 billion. "The third quarter marked anot
11/4/24 4:01:00 PM ET
$VRTX
Biotechnology: Pharmaceutical Preparations
Health Care
Vertex to Participate in Upcoming November Investor Conferences
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in two upcoming investor conferences. Dr. Reshma Kewalramani, Chief Executive Officer and President, will participate in a fireside chat at the Guggenheim Inaugural Healthcare Innovation Conference on Tuesday, November 12, 2024 at 9:00 a.m. ET. Stuart A. Arbuckle, Executive Vice President and Chief Operating Officer, will participate in a fireside chat at the Stifel Healthcare Conference on Tuesday, November 19, 2024 at 8:00 a.m. ET. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A rep
10/29/24 4:05:00 PM ET
$VRTX
Biotechnology: Pharmaceutical Preparations
Health Care
Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress
- New data on povetacicept 80 mg SC Q4 weeks in IgA nephropathy shows mean UPCR reduction from baseline of 66% observed at 48 weeks, associated with stable renal function (eGFR) and 63% achieving clinical remission -- - First proteinuria data on povetacicept in primary membranous nephropathy shows mean UPCR reduction from baseline of 62% at 24 weeks – - Global Phase 3 RAINIER trial of povetacicept in IgA nephropathy now underway – – Enrollment and dosing ongoing in Phase 3 portion of the global Phase 2/3 pivotal clinical trial of inaxaplin for the treatment of APOL1-mediated kidney disease – Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today provided updates on multiple kidney dise
10/25/24 1:00:00 PM ET
$VRTX
Biotechnology: Pharmaceutical Preparations
Health Care

$VRTX
Financials

Live finance-specific insights

Vertex Reports Third Quarter 2024 Financial Results
— Product revenue of $2.77 billion, a 12% increase compared to Q3 2023 — — Raising full-year product revenue guidance to $10.8 billion to $10.9 billion — — Preparing for two potential near-term launches: vanzacaftor triple in CF and suzetrigine (VX-548) for moderate-to-severe acute pain — — Pipeline progress continuing with three additional programs advancing to Phase 3: suzetrigine in DPN, povetacicept in IgAN and VX-880 in T1D — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the third quarter ended September 30, 2024, and raised its full-year product revenue guidance to $10.8 billion to $10.9 billion. "The third quarter marked anot
11/4/24 4:01:00 PM ET
$VRTX
Biotechnology: Pharmaceutical Preparations
Health Care
Vertex to Announce Third Quarter 2024 Financial Results on November 4th
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its third quarter 2024 financial results on Monday, November 4, 2024 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Third Quarter 2024 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived web
10/10/24 4:05:00 PM ET
$VRTX
Biotechnology: Pharmaceutical Preparations
Health Care
Vertex Reports Second Quarter 2024 Financial Results
— Product revenue of $2.65 billion, a 6% increase compared to Q2 2023 — — Company raises full year product revenue guidance to $10.65 to $10.85 billion — — FDA accepted NDA for vanzacaftor triple in CF with Priority Review and PDUFA target action date of January 2, 2025; additionally, MAA submissions validated in EU and U.K. — — FDA accepted NDA for suzetrigine (VX-548) for moderate-to-severe acute pain with Priority Review and PDUFA target action date of January 30, 2025 — — Advancing broad and deep clinical pipeline with multiple milestones expected in H2:24 — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the second quarter e
8/1/24 4:01:00 PM ET
$VRTX
Biotechnology: Pharmaceutical Preparations
Health Care

FDA Approval for TRIKAFTA issued to VERTEX PHARMS INC

Products on NDA 217660

Approval Date(s) and History, Letters, Labels, Reviews for NDA 217660

Original Approvals or Tentative Approvals

Chat with this insight

Recent Analyst Ratings for $VRTX

$VRTX FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

FDA Approval for TRIKAFTA (COPACKAGED) issued to VERTEX PHARMS INC

FDA Approval for TRIKAFTA (COPACKAGED) issued to VERTEX PHARMS INC

$VRTX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

$VRTX Leadership Updates

Live Leadership Updates

Vertex Appoints Nancy Thornberry to its Board of Directors

Vertex Appoints Michel Lagarde to its Board of Directors

Vertex Appoints E. Morrey Atkinson, Ph.D., to EVP and Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations

$VRTX Press Releases

Fastest customizable press release news feed in the world

Vertex Reports Third Quarter 2024 Financial Results

Vertex to Participate in Upcoming November Investor Conferences

Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress

$VRTX Financials

Live finance-specific insights

Vertex Reports Third Quarter 2024 Financial Results

Vertex to Announce Third Quarter 2024 Financial Results on November 4th

Vertex Reports Second Quarter 2024 Financial Results

$VRTX SEC Filings

SEC Form 10-Q filed by Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 144 filed by Vertex Pharmaceuticals Incorporated

$VRTX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP, Chief Scientific Officer Altshuler David sold $7,178 worth of shares (15 units at $478.56), decreasing direct ownership by 0.06% to 25,813 units (SEC Form 4)

EVP & Chief Financial Officer Wagner Charles F Jr sold $1,554,810 worth of shares (3,000 units at $518.27), decreasing direct ownership by 6% to 44,137 units (SEC Form 4)

CEO & President Kewalramani Reshma sold $7,826,970 worth of shares (15,198 units at $515.00), decreasing direct ownership by 17% to 75,772 units (SEC Form 4)

$VRTX Market Insights

Live Market Insights

TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $500

Here's How Much $100 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth Today

Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $480

$VRTX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Citigroup initiated coverage on Vertex Pharma with a new price target

Scotiabank initiated coverage on Vertex Pharma

Raymond James resumed coverage on Vertex Pharma

Recent Analyst Ratings for
$VRTX

$VRTX
FDA approvals

$VRTX
Large Ownership Changes

$VRTX
Leadership Updates

$VRTX
Press Releases

$VRTX
Financials

$VRTX
SEC Filings

$VRTX
Insider Trading

$VRTX
Market Insights

$VRTX
Analyst Ratings